Gross Profit, Operating Income, and Net Income as a percentage of Revenue

Operating Margin

Profit Margin

Margins

An operating expense is an expense a business incurs through its normal business operations. Often abbreviated as OPEX.

Operating Expenses

Year over year growth in Revenue and Operating Expenses.

Revenue Y/Y

OpEx Y/Y

Growth

Shares outstanding refer to a company's stock currently held by all its shareholders, including share blocks held by institutional investors and restricted shares owned by the company's officers and insiders.

Outstanding Shares

Market Cap

Also known as Price/Sales Ratio. Calculated using Average market cap for the quarter / Annualized quarterly revenue.

Revenue Multiple

Intellia Therapeutics

Intellia Therapeutics, Inc. is a clinical stage genome editing company, which engages in the development of curative therapeutics using the CRISPR/Cas9 system. Its CRISPR/Cas9 system transforms medicine by both producing therapeutics that permanently edit and/or correct disease-associated genes in the human body with a single treatment course, and creates engineered cells that can treat oncological and immunological diseases. The company was founded by Andrew May, Luciano Marraffini, Rodolphe Barrangou, Nessan Bermingham, Rachel Haurwitz, Erik Sontheimer, Jennifer Doudna, and Derrick Rossi in May 2014 and is headquartered in Cambridge, MA.

Earnings data Q1 2021

Earnings data Q2 2021

Earnings data Q3 2021

Earnings data Q4 2021

Earnings data Q1 2022

Earnings data Q2 2022

Earnings data Q3 2022

Earnings data Q4 2022

Earnings data Q1 2023

Earnings data Q2 2023

Earnings data Q3 2023

Earnings data Q4 2023

Earnings data Q1 2024

Earnings data Q2 2024

Earnings data Q3 2024

Earnings data Q4 2024

Intellia Therapeutics excels in CRISPR trials, faces regulatory challenges

Intellia Therapeutics showcased promising clinical trial results, a strong financial position, and a commitment to advancing CRISPR-based therapies. While facing regulatory and strategic challenges, the company is well-positioned to capitalize on opportunities in gene editing technologies and global trials.

Intellia Therapeutics advances CRISPR therapies with strong financials and global interest

Intellia Therapeutics is making significant progress in advancing their CRISPR-based therapies, with strong financials and promising global interest in their programs. Challenges include dose selection and trial specifics, while opportunities exist in data presentation, regulatory acceleration, and therapeutic approaches.

Intellia Therapeutics reports strong Q2 performance and eyes global expansion

Intellia Therapeutics reported strong financials, progress in clinical programs, and positive patient outcomes. Challenges include pending decisions and regulatory factors. Opportunities exist in expanding market reach and monitoring industry developments.

Intellia Therapeutics progresses with NTLA-2001, faces competition challenges

Intellia Therapeutics demonstrated significant progress in drug development with FDA clearance for Phase 3 trial of NTLA-2001 and positive interim data, supported by a strong financial position.
The company's adaptability, collaborations, and focus on efficacy position it well for future growth, despite challenges in understanding treatment benefits and addressing competition.
Opportunities lie in robust trial designs, potential synergies with RNA silencers, sustained financial support, and enhancing treatment outcomes and patient experience.
Analysts' interest in trial details and future prospects underscores confidence in Intellia's advancements and potential impact in the biotech industry.

Intellia Therapeutics excels in 2023, eyes CRISPR breakthroughs in 2024

Intellia Therapeutics had a strong financial year with a focus on advancing CRISPR-based therapies.
Confidence in pivotal study designs and collaborations present growth opportunities for the company.
Challenges include revenue adjustments and regulatory uncertainties that need to be navigated.
Overall, Intellia's strategic focus on genome editing and disease targets positions it well for future success.

Revenue

Cost of revenue

Gross profit

Operating expenses

SG&A

Other

Operating income

EBITDA

Net income

Earnings per share

Total assets

Current assets

Cash & equivalents

Receivables

Inventory

Non-current assets

Net PPE

Intangibles

Total liabilities

Current liabilities

Short term debt

Income tax payable

Non-current liabilities

Long-term debt

Total equity

Stockholders equity

Minority interest

Total liabilities & equity

Total debt

Net debt

Book value per share

Cash from operations

Funds from operations

Change in working capital

Cash from investing

Capital expenditure

Purchase/sale of investments

Purchase/sale of business

Other sources

Cash from financing

Change in stock

Change in debt

Cash dividends paid

Cash from other sources

Net change in cash

Free cash flow

Amid yet another soft session on Wall Street, biotechnology firm Intellia Therapeutics (NASDAQ: NTLA ) brightened the room considerably. Receiving a regulatory green light from the Food and Drug Administration (FDA), Intellia can now begin testing its CRISPR gene-editing technology in human patients.

Why Is Intellia Therapeutics (NTLA) Stock Up 10% Today?

Intellia Therapeutics landed a historic regulatory nod from the FDA.

Why Intellia Therapeutics Stock Jumped This Week

The FDA cleared Intellia to begin testing its CRISPR gene-editing technology in people on Thursday, leading NTLA stock to jump. The post Intellia Therapeutics Stock Surges On A First-Ever In CRISPR Gene Editing appeared first on Investor's Business Daily.

Intellia Therapeutics Stock Surges On A First-Ever In CRISPR Gene Editing

Shares of Intellia Therapeutics Inc. NTLA, +1.44% rallied about 10% in premarket trading on Thursday after the company said the Food and Drug Administration will allow its experimental CRISPR therapy to move into the Phase 2 part of the Phase 1/2 clinical trial. The single-dose therapy is being assessed as a treatment for hereditary angioedema, a rare disorder that causes severe swelling.

Intellia's stock jumps as CRISPR therapy moves into Phase 2 clinical trial

NTLA-2002 is a single dose, in vivo genome editing candidate designed to prevent potentially life-threatening swelling attacks in people with HAE NTLA-2002 is a single dose, in vivo genome editing candidate designed to prevent potentially life-threatening swelling attacks in people with HAE

Intellia Therapeutics Announces FDA Clearance of Investigational New Drug (IND) Application for NTLA-2002, an In Vivo CRISPR-Based Investigational Therapy for the Treatment of Hereditary Angioedema (HAE)

Intellia Therapeutics (NTLA) reports loss for fourth-quarter 2022, in line with estimates.

Intellia's (NTLA) Q4 Loss Matches Estimates, Revenues Up Y/Y

Intellia Therapeutics, Inc. (NASDAQ:NTLA ) Q4 2022 Results Conference Call February 23, 2023 8:00 AM ET Company Participants Ian Karp - Senior Vice President, Investor Relations and Corporate Communications John Leonard - Chief Executive Officer David Lebwohl - Chief Medical Officer Laura Sepp-Lorenzino - Chief Scientific Officer Glenn Goddard - Chief Financial Officer Conference Call Participants Maury Raycroft - Jeffries Greg Harrison - Bank of America Swapnil Malekar - Piper Sandler Terence Flynn - Morgan Stanley Yanan Zhu - Wells Fargo Rick Bienkowski - Cantor Fitzgerald Raju Prasad - William Blair Dae Gon Ha - Stifel Debjit Chattopadhyay - Guggenheim Rich Law - Credit Suisse Jay Olson - Oppenheimer Brian Cheng - JP Morgan Joseph Thome - Cowen & Company Operator Good morning and welcome to the Intellia Therapeutics' Fourth Quarter and Full Year 2022 Financial Results Conference Call. My name is Drew and I will be your conference operator today.

Intellia Therapeutics, Inc. (NTLA) Q4 2022 Earnings Call Transcript

Intellia Therapeutics, Inc. (NTLA) delivered earnings and revenue surprises of 0% and 11.06%, respectively, for the quarter ended December 2022. Do the numbers hold clues to what lies ahead for the stock?

Intellia Therapeutics, Inc. (NTLA) Reports Q4 Loss, Tops Revenue Estimates

CAMBRIDGE, Mass., Feb. 23, 2023 (GLOBE NEWSWIRE) -- Intellia Therapeutics, Inc. (NASDAQ:NTLA), a leading clinical-stage genome editing company focused on developing potentially curative therapies leveraging CRISPR-based technologies, today reported operational highlights and financial results for the fourth quarter and year ended December 31, 2022.

Intellia Therapeutics Announces Fourth Quarter and Full-Year 2022 Financial Results and Highlights Recent Company Progress

Here is how Intellia Therapeutics, Inc. (NTLA) and Centogene N.V. (CNTG) have performed compared to their sector so far this year.

Is Intellia Therapeutics (NTLA) Stock Outpacing Its Medical Peers This Year?

Denali Therapeutics

Zai Lab Ltd.

Over the next 10 to 20 years, some of healthcare's most impactful innovations will come from biotechnology companies. They'll produce medicines based on living organisms that will save and improve the lives of millions of patients with a wide range of diseases.

3 More Mid-Cap Biotechs The Street Sees Doubling

Beam Therapeutics

The two clinical-stage gene-editing companies have good long-term prospects.

Better Buy: Beam Therapeutics or Intellia Therapeutics?

Intellia Therapeutics, Inc. (NTLA) possesses the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.

Intellia Therapeutics, Inc. (NTLA) Expected to Beat Earnings Estimates: Should You Buy?

CAMBRIDGE, Mass., Feb. 16, 2023 (GLOBE NEWSWIRE) -- Intellia Therapeutics, Inc. (NASDAQ:NTLA), a leading clinical-stage genome editing company focused on developing potentially curative therapeutics leveraging CRISPR-based technologies, will present its fourth quarter and full-year 2022 financial results and operational highlights in a conference call on February 23, 2023, at 8 a.m. ET.

Intellia Therapeutics to Hold Conference Call to Discuss Fourth Quarter and Full-Year 2022 Earnings and Company Updates

PDS Biotechnology Corporation

Verve Therapeutics

These cutting-edge biotech stocks hold tremendous upside potential.

3 Deeply Undervalued Stocks That Could Double Your Money

COMPASS Pathways

Ginkgo Bioworks Holdings

These stocks are risky. But they just might deliver huge gains if analysts are right.

3 Cathie Wood Stocks That Could More Than Double in 12 Months, According to Wall Street

The mean of analysts' price targets for Intellia Therapeutics, Inc. (NTLA) points to a 145.3% upside in the stock. While this highly sought-after metric has not proven reasonably effective, strong agreement among analysts in raising earnings estimates does indicate an upside in the stock.

Wall Street Analysts Believe Intellia Therapeutics, Inc. (NTLA) Could Rally 145.32%: Here's is How to Trade

ARK Innovation ETF

CRISPR Therapeutics

Cathie Wood is bullish about these stocks. And so are Wall Street analysts.

3 Cathie Wood Stocks Wall Street Thinks Can Soar 60% to 129%

Allogene Therapeutics Inc

Editas Medicine

Seagen

Let us look at some biotech stocks, ALLO, EDIT, NTLA and SGEN that are poised to beat on fourth-quarter earnings.

4 Biotech Stocks Set to Outpace Q4 Earnings Estimates

Cellectis SA

Sangamo Therapeutics

CRISPR technology has the potential to revolutionize the way we approach medicine. This technology has already been used in a variety of applications, including gene editing, gene therapy, and disease diagnosis.

7 CRISPR Stocks With the Best Long-Term Potential

AbbVie

To many investors, gene editing sounds like the plot of a science fiction movie. The concept of being able to edit our DNA to cure genetic diseases is quite unbelievable, and the upside of gene editing to treat rare diseases is impressive.

3 Gene Editing Stocks to Buy Now OR You'll Be Kicking Yourself Later

Global X Genomics & Biotechnology ETF

Gene editing stocks present themselves as one of the more lucrative investments in the healthcare sector. Gene editing, a revolutionary take on the science of genetic engineering, has the potential to countless lives around the globe.

3 Gene Editing Stocks With the Best Long-Term Potential

The consensus price target hints at an 185.4% upside potential for Intellia Therapeutics, Inc. (NTLA). While empirical research shows that this sought-after metric is hardly effective, an upward trend in earnings estimate revisions could mean that the stock will witness an upside in the near term.

Does Intellia Therapeutics, Inc. (NTLA) Have the Potential to Rally 185.4% as Wall Street Analysts Expect?

CAMBRIDGE, Mass., Jan. 11, 2023 (GLOBE NEWSWIRE) -- Intellia Therapeutics, Inc. (NASDAQ:NTLA), a leading clinical-stage genome editing company focused on developing potentially curative therapies leveraging CRISPR-based technologies, today announced the U.K. Medicines and Healthcare products Regulatory Agency (MHRA) has awarded the Innovation Passport for NTLA-2002, an in vivo genome editing candidate being developed for the treatment of hereditary angioedema (HAE). The Innovation Passport is the point of entry into the U.K.'s Innovative Licensing and Access Pathway (ILAP), which is designed to accelerate time to market and facilitate patient access to innovative medicines.

Intellia Therapeutics Awarded Innovation Passport in the United Kingdom for NTLA-2002, an Investigational Genome Editing Treatment for Hereditary Angioedema

AMC Entertainment

Global Business Travel Group I

Guardant Health Inc

Immunovant Inc

Maxar Technologies

Madrigal Pharmaceuticals

Mirati Therapeutics

Rumble Inc

Prometheus Biosciences

Mid-cap companies are fast-growing, young companies that are not as volatile as small-cap and not as stable as large-cap companies.

News for Intellia Therapeutics Stock (NTLA)